Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study

Overview

Journal J Clin Sleep Med

Specialties Neurology
Psychiatry

Date 2016 Oct 28

PMID 27784414

Citations 2

Authors

Jack D Edinger

Rachel Manber

Daniel J Buysse

Andrew D Krystal

Michael E Thase

Phillip Gehrman

Christopher P Fairholme

James Luther

Stephen Wisniewski

Affiliations

Soon will be listed here.

Abstract

Study Objectives: To determine if patients with childhood onsets (CO) of both major depression and insomnia disorder show blunted depression and insomnia treatment responses to concurrent interventions for both disorders compared to those with adult onsets (AO) of both conditions.

Methods: This study was a secondary analysis of data obtained from a multisite randomized clinical trial designed to test the efficacy of combining a psychological/behavior insomnia therapy with antidepressant medication to enhance depression treatment outcomes in patients with comorbid major depression and insomnia. This study included 27 adults with CO of depression and insomnia and 77 adults with AO of both conditions. They underwent a 16-week treatment including: (1) a standardized two-step pharmacotherapy for depression algorithm, consisting of escitalopram, sertraline, and desvenlafaxine in a prescribed sequence; and (2) either cognitive behavioral insomnia therapy (CBT-I) or a quasi-desensitization control (CTRL) therapy. Main outcome measures were the 17-item Hamilton Rating Scale for Depression (HRSD-17) and the Insomnia Severity Index (ISI) completed pre-treatment and every 2 weeks thereafter.

Results: The AO and CO groups did not differ significantly in regard to their pre-treatment HRSD-17 and ISI scores. Mixed model analyses that adjusted for the number of insomnia treatment sessions attended showed that the AO group achieved significantly lower, subclinical scores on the HRSD-17 and ISI than did the CO group by the time of study exit. Moreover, a significant group by treatment arm interaction suggested that HRSD-17 scores at study exit remained significantly higher in the CO group receiving the CTRL therapy than was the case for the participants in the CO group receiving CBT-I. Greater proportions of the AO group achieved a priori criteria for remission of insomnia (49.3% vs. 29.2%, p = 0.04) and depression (45.5% vs. 29.6%, p = 0.07) than did those in the CO group.

Conclusions: Patients with comorbid depression and insomnia who experienced the first onset of both disorders in childhood are less responsive to the treatments offered herein than are those with adult onsets of these comorbid disorders. Further research is needed to identify therapies that enhance the depression and insomnia treatment responses of those with childhood onsets of these two conditions.

Citing Articles

Sleep and Mood Disorders Among Youth.

Asarnow L, Mirchandaney R Child Adolesc Psychiatr Clin N Am. 2020; 30(1):251-268.

PMID: 33223065 PMC: 8386498. DOI: 10.1016/j.chc.2020.09.003.

Cognitive Behavioral Therapy for Insomnia in Depression.

Asarnow L, Manber R Sleep Med Clin. 2019; 14(2):177-184.

PMID: 31029185 PMC: 6487874. DOI: 10.1016/j.jsmc.2019.01.009.

References

Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L . Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163(1):28-40. DOI: 10.1176/appi.ajp.163.1.28. View

Bastien C, Vallieres A, Morin C . Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001; 2(4):297-307. DOI: 10.1016/s1389-9457(00)00065-4. View

Sunderajan P, Gaynes B, Wisniewski S, Miyahara S, Fava M, Akingbala F . Insomnia in patients with depression: a STAR*D report. CNS Spectr. 2010; 15(6):394-404. DOI: 10.1017/s1092852900029266. View

Nierenberg A, Keefe B, Leslie V, Alpert J, Pava J, Worthington 3rd J . Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999; 60(4):221-5. DOI: 10.4088/jcp.v60n0403. View

Akiskal H, King D, Rosenthal T, Robinson D . Chronic depressions. Part 1. Clinical and familial characteristics in 137 probands. J Affect Disord. 1981; 3(3):297-315. DOI: 10.1016/0165-0327(81)90031-8. View

Steinmark S, Borkovec T . Active and placebo treatment effects on moderate insomnia under counterdemand and positive demand instructions. J Abnorm Psychol. 1974; 83(2):157-63. DOI: 10.1037/h0036489. View

Hamilton M . Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967; 6(4):278-96. DOI: 10.1111/j.2044-8260.1967.tb00530.x. View

Hollon S, Shelton R, Wisniewski S, Warden D, Biggs M, Friedman E . Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. J Psychiatr Res. 2005; 40(1):59-69. PMC: 5886709. DOI: 10.1016/j.jpsychires.2005.07.008. View

Manber R, Edinger J, Gress J, San Pedro-Salcedo M, Kuo T, Kalista T . Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep. 2008; 31(4):489-95. PMC: 2279754. DOI: 10.1093/sleep/31.4.489. View

10.

Thase M, Buysse D, Frank E, Cherry C, Cornes C, Mallinger A . Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry. 1997; 154(4):502-9. DOI: 10.1176/ajp.154.4.502. View

11.

Carney C, Segal Z, Edinger J, Krystal A . A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry. 2007; 68(2):254-60. DOI: 10.4088/jcp.v68n0211. View

12.

Morin C, Belleville G, Belanger L, Ivers H . The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011; 34(5):601-8. PMC: 3079939. DOI: 10.1093/sleep/34.5.601. View

13.

Dew M, Reynolds 3rd C, Houck P, Hall M, Buysse D, Frank E . Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry. 1997; 54(11):1016-24. DOI: 10.1001/archpsyc.1997.01830230050007. View

14.

Nierenberg A, Husain M, Trivedi M, Fava M, Warden D, Wisniewski S . Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2009; 40(1):41-50. PMC: 5886713. DOI: 10.1017/S0033291709006011. View

15.

Jang S, Jung S, Pae C, Kimberly B, Nelson J, Patkar A . Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS). J Affect Disord. 2013; 151(3):854-9. DOI: 10.1016/j.jad.2013.07.023. View

16.

Rush A, Kraemer H, Sackeim H, Fava M, Trivedi M, Frank E . Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006; 31(9):1841-53. DOI: 10.1038/sj.npp.1301131. View

17.

Regestein Q, Reich P . Incapacitating childhood-onset insomnia. Compr Psychiatry. 1983; 24(3):244-8. DOI: 10.1016/0010-440x(83)90075-5. View

18.

Manber R, Buysse D, Edinger J, Krystal A, Luther J, Wisniewski S . Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial. J Clin Psychiatry. 2016; 77(10):e1316-e1323. DOI: 10.4088/JCP.15m10244. View

19.

Hedges D, Brown B, Shwalb D . A direct comparison of effect sizes from the clinical global impression-improvement scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder. Hum Psychopharmacol. 2008; 24(1):35-40. DOI: 10.1002/hup.989. View

20.

Thase M . Depression, sleep, and antidepressants. J Clin Psychiatry. 1998; 59 Suppl 4:55-65. View